AR072003A1 - Efectos antitumorales de combinaciones cannabinoides - Google Patents
Efectos antitumorales de combinaciones cannabinoidesInfo
- Publication number
- AR072003A1 AR072003A1 ARP090102000A ARP090102000A AR072003A1 AR 072003 A1 AR072003 A1 AR 072003A1 AR P090102000 A ARP090102000 A AR P090102000A AR P090102000 A ARP090102000 A AR P090102000A AR 072003 A1 AR072003 A1 AR 072003A1
- Authority
- AR
- Argentina
- Prior art keywords
- cbd
- thc
- use according
- cannabinoid
- cannabinoids
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 4
- 239000003557 cannabinoid Substances 0.000 title abstract 4
- 230000000259 anti-tumor effect Effects 0.000 title 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 4
- 229950011318 cannabidiol Drugs 0.000 abstract 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 4
- 229960004242 dronabinol Drugs 0.000 abstract 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229940065144 cannabinoids Drugs 0.000 abstract 2
- 208000005017 glioblastoma Diseases 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Abstract
Se refiere al uso de una combinacion de cannabinoides, particularmente tetrahidrocannabinol (THC) y cannabidiol (CBD) en la fabricacion de un medicamento para el uso en el tratamiento de c ncer. En particular, el c ncer tratado es un tumor cerebral, m s particularmente un glioma, aun m s particularmente un glioblastoma multiforme (GBM). Reivindicacion 3: El uso de acuerdo con la reivindicacion 2, caracterizado porque THC y CBD est n en una relacion de entre 20:1 y 1:20 (THC:CBD). Reivindicacion 6: El uso de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque cada cannabinoide se usa en un nivel que ser¡a considerado suboptimo si se usara solo. Reivindicacion 10: El uso de acuerdo con la reivindicacion 1, caracterizado porque el uno o varios cannabinoides est n presentes como extractos vegetales, como compuestos puros o una combinacion de ambos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0810195.8A GB2471987B (en) | 2008-06-04 | 2008-06-04 | Anti-tumoural effects of cannabinoid combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072003A1 true AR072003A1 (es) | 2010-07-28 |
Family
ID=39638149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102000A AR072003A1 (es) | 2008-06-04 | 2009-06-03 | Efectos antitumorales de combinaciones cannabinoides |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8632825B2 (es) |
| EP (2) | EP2318000A1 (es) |
| JP (1) | JP5611196B2 (es) |
| KR (2) | KR20160103148A (es) |
| CN (1) | CN102083430B (es) |
| AR (1) | AR072003A1 (es) |
| AU (1) | AU2009254936B2 (es) |
| BR (1) | BRPI0913384A2 (es) |
| CA (1) | CA2726258C (es) |
| CO (1) | CO6382172A2 (es) |
| GB (1) | GB2471987B (es) |
| IL (1) | IL209738B (es) |
| MX (1) | MX2010012557A (es) |
| MY (1) | MY156444A (es) |
| NZ (1) | NZ589228A (es) |
| RU (1) | RU2546284C2 (es) |
| SG (2) | SG191644A1 (es) |
| TW (1) | TWI445531B (es) |
| UA (1) | UA104426C2 (es) |
| WO (1) | WO2009147439A1 (es) |
| ZA (1) | ZA201008556B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
| GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2475183B (en) * | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB201117956D0 (en) | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
| EP2719375A1 (en) * | 2012-10-10 | 2014-04-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
| EP2934512B1 (en) | 2012-12-18 | 2021-11-24 | Kotzker Consulting LLC | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| GB2516814B (en) | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
| EP3552482B1 (en) | 2013-10-29 | 2022-06-29 | Biotech Institute, LLC | Breeding, production, processing and use of specialty cannabis |
| US11224660B2 (en) | 2014-05-29 | 2022-01-18 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| WO2016054268A1 (en) | 2014-09-30 | 2016-04-07 | MJAR Holdings, LLC | Methods of growing cannabaceae plants using artificial lighting |
| US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
| AU2016211314A1 (en) | 2015-01-31 | 2017-08-17 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
| EP3067058A1 (en) | 2015-03-13 | 2016-09-14 | Farmagens Health Care Srl | Biological composition based on engineered lactobacillus paracasei subsp. paracasei f19 for the biosynthesis of cannabinoids |
| KR20180021718A (ko) | 2015-05-28 | 2018-03-05 | 트위드 인크. | Thca 신타제의 변형된 발현을 갖는 칸나비스 식물 |
| US10123973B2 (en) * | 2015-06-11 | 2018-11-13 | Mashhad University Of Medical Science | Liposome composition for cancer treatment |
| AU2016276563A1 (en) * | 2015-06-11 | 2018-01-04 | One World Cannabis Ltd | Novel cannabinoid combination therapies for multiple myeloma (MM) |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| MX2018000844A (es) * | 2015-07-22 | 2018-07-06 | Phytopharma Int Ltd | Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera. |
| EP3153160B1 (en) | 2015-10-08 | 2021-08-11 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| CA3187317A1 (en) | 2015-10-27 | 2017-05-04 | Jay Pharma, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
| IL299047A (en) * | 2015-11-24 | 2023-02-01 | Constance Therapeutics Inc | Cannabis fat preparations and methods for their preparation |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| CA3056286A1 (en) * | 2017-03-16 | 2018-09-20 | CannTab Therapeutics Limited | Modified release multi-layer tablet cannabinoid formulations |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
| WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020129043A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis sativa lines and extracts with anti-cancer properties |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| IL272078A (en) * | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
| CN111773390B (zh) * | 2020-07-01 | 2021-08-20 | 南京大学 | 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用 |
| WO2022225658A1 (en) * | 2021-04-19 | 2022-10-27 | The Regents Of The University Of California | Cannabis limits cancer stem cell growth in poorly differentiated cancers |
| WO2023062634A1 (en) * | 2021-10-13 | 2023-04-20 | G.R.I.N Ultra Ltd | Compositions comprising cannabinoids and methods of use thereof in the treatment of cancer |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
| ES2164584A1 (es) * | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Terapia con cannabinoides para el tratamiento de tumores cerebrales. |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| AU2001290949A1 (en) | 2000-09-14 | 2002-03-26 | California Pacific Medical Center | Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma |
| US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
| CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| US20080057117A1 (en) | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
| IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
| US7285687B2 (en) | 2002-04-25 | 2007-10-23 | Virginia Commonwealth University | Cannabinoids |
| US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| GB2418612A (en) | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| AU2006231452B2 (en) | 2005-04-01 | 2011-05-26 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
| US7968594B2 (en) | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
| AU2006247526A1 (en) | 2005-05-13 | 2006-11-23 | Unimed Pharmaceuticals, Inc. | Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting |
| GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
| GB2475183B (en) | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
| GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
-
2008
- 2008-06-04 GB GB0810195.8A patent/GB2471987B/en active Active
-
2009
- 2009-06-03 AR ARP090102000A patent/AR072003A1/es unknown
- 2009-06-03 TW TW098118351A patent/TWI445531B/zh active
- 2009-06-04 UA UAA201015971A patent/UA104426C2/uk unknown
- 2009-06-04 KR KR1020167022577A patent/KR20160103148A/ko not_active Application Discontinuation
- 2009-06-04 CN CN200980120759.0A patent/CN102083430B/zh active Active
- 2009-06-04 EP EP09757811A patent/EP2318000A1/en not_active Withdrawn
- 2009-06-04 CA CA2726258A patent/CA2726258C/en active Active
- 2009-06-04 US US12/996,124 patent/US8632825B2/en active Active
- 2009-06-04 AU AU2009254936A patent/AU2009254936B2/en active Active
- 2009-06-04 WO PCT/GB2009/050621 patent/WO2009147439A1/en active Application Filing
- 2009-06-04 JP JP2011512222A patent/JP5611196B2/ja active Active
- 2009-06-04 EP EP20201377.7A patent/EP3785710A1/en active Pending
- 2009-06-04 RU RU2010153576/15A patent/RU2546284C2/ru not_active IP Right Cessation
- 2009-06-04 MX MX2010012557A patent/MX2010012557A/es active IP Right Grant
- 2009-06-04 KR KR1020117000057A patent/KR101801639B1/ko active IP Right Grant
- 2009-06-04 SG SG2013043096A patent/SG191644A1/en unknown
- 2009-06-04 SG SG2013082474A patent/SG195650A1/en unknown
- 2009-06-04 MY MYPI2010005534A patent/MY156444A/en unknown
- 2009-06-04 BR BRPI0913384-4A patent/BRPI0913384A2/pt not_active Application Discontinuation
- 2009-06-04 NZ NZ589228A patent/NZ589228A/xx unknown
-
2010
- 2010-11-29 ZA ZA2010/08556A patent/ZA201008556B/en unknown
- 2010-12-02 IL IL209738A patent/IL209738B/en active IP Right Grant
- 2010-12-15 CO CO10157623A patent/CO6382172A2/es not_active Application Discontinuation
-
2013
- 2013-11-14 US US14/079,994 patent/US20140287067A1/en not_active Abandoned
-
2015
- 2015-01-14 US US14/596,725 patent/US20150313867A1/en not_active Abandoned
-
2019
- 2019-06-07 US US16/434,616 patent/US20200138771A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072003A1 (es) | Efectos antitumorales de combinaciones cannabinoides | |
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| CO2019013887A2 (es) | Composiciones y tratamientos para el trastorno del sueño | |
| CR10408A (es) | Composiciones novedosas para el trastornos del cabello y procedimiento de preparacion de las mismas | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| NZ597704A (en) | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| ECSP088866A (es) | Uso de inhibidores de dpp iv | |
| JP2012532093A5 (es) | ||
| UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
| EA201290975A1 (ru) | Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии | |
| AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
| AR058130A1 (es) | Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer | |
| NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
| UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| TR201905480T4 (tr) | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. | |
| ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| EA201001288A1 (ru) | Лечение гипертонии 25-гидроксивитамином d3 | |
| ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
| ECSP109968A (es) | Depsipéptidos cíclicos | |
| CL2008002946A1 (es) | Compuestos derivados de quinazolindionas sustituidas, inhibidores pde7 y pde8; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y usos en el tratamiento y/o prevencion de enfermedades inflamatorias, inmuno inflamatorias, gi, oseas, cancer, entre otras. | |
| MX2020004232A (es) | Composiciones de cannabinoides y sus metodos de uso. | |
| GT200600106A (es) | Agentes endoparasiticidas | |
| BR112014003264A2 (pt) | composições nutricionais compreendendo uma fibra viscosa solúvel e um extrato de planta contendo polifenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |